1. Home
  2. OLLI vs IONS Comparison

OLLI vs IONS Comparison

Compare OLLI & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OLLI
  • IONS
  • Stock Information
  • Founded
  • OLLI 1982
  • IONS 1989
  • Country
  • OLLI United States
  • IONS United States
  • Employees
  • OLLI N/A
  • IONS N/A
  • Industry
  • OLLI Department/Specialty Retail Stores
  • IONS Biotechnology: Pharmaceutical Preparations
  • Sector
  • OLLI Consumer Discretionary
  • IONS Health Care
  • Exchange
  • OLLI Nasdaq
  • IONS Nasdaq
  • Market Cap
  • OLLI 6.1B
  • IONS 6.0B
  • IPO Year
  • OLLI 2015
  • IONS 1991
  • Fundamental
  • Price
  • OLLI $92.79
  • IONS $36.95
  • Analyst Decision
  • OLLI Strong Buy
  • IONS Buy
  • Analyst Count
  • OLLI 12
  • IONS 18
  • Target Price
  • OLLI $104.92
  • IONS $62.00
  • AVG Volume (30 Days)
  • OLLI 972.2K
  • IONS 1.1M
  • Earning Date
  • OLLI 12-04-2024
  • IONS 11-06-2024
  • Dividend Yield
  • OLLI N/A
  • IONS N/A
  • EPS Growth
  • OLLI 36.60
  • IONS N/A
  • EPS
  • OLLI 3.28
  • IONS N/A
  • Revenue
  • OLLI $2,216,192,000.00
  • IONS $803,067,000.00
  • Revenue This Year
  • OLLI $10.91
  • IONS N/A
  • Revenue Next Year
  • OLLI $11.11
  • IONS $16.31
  • P/E Ratio
  • OLLI $28.09
  • IONS N/A
  • Revenue Growth
  • OLLI 14.15
  • IONS 30.57
  • 52 Week Low
  • OLLI $68.05
  • IONS $35.95
  • 52 Week High
  • OLLI $104.98
  • IONS $54.44
  • Technical
  • Relative Strength Index (RSI)
  • OLLI 41.58
  • IONS 39.33
  • Support Level
  • OLLI $91.16
  • IONS $37.18
  • Resistance Level
  • OLLI $101.12
  • IONS $40.07
  • Average True Range (ATR)
  • OLLI 2.68
  • IONS 1.19
  • MACD
  • OLLI -0.07
  • IONS -0.02
  • Stochastic Oscillator
  • OLLI 20.72
  • IONS 10.74

About OLLI Ollie's Bargain Outlet Holdings Inc.

Ollie's Bargain Outlet Holdings Inc is a retailer of brand-name merchandise at drastically reduced prices. It offers customers a selection of brand-name products, including housewares, food, books and stationery, bed and bath, floor coverings, toys, and hardware. It operates stores across the Eastern half of the United States. Its differentiated go-to-market plan is characterized by a fun, and engaging treasure hunt shopping experience, compelling customer value proposition, and witty, humorous in-store signage and advertising campaigns. These attributes have driven rapid growth and consistent store performance for the company.

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.

Share on Social Networks: